Related references
Note: Only part of the references are listed.Melanoma Resistance: A Bright Future for Academicians and a Challenge for Patient Advocates
Andrzej T. Slominski et al.
MAYO CLINIC PROCEEDINGS (2014)
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors
Alexander Eggermont et al.
ONCOIMMUNOLOGY (2014)
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
Vafa Shahabi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Societal preference values for advanced melanoma health states in the United Kingdom and Australia
K. M. Beusterien et al.
BRITISH JOURNAL OF CANCER (2009)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
MF Avril et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Economic impact of neutropenia and febrile neutropenia in breast cancer: Estimates from two national databases
SK Gandhi et al.
PHARMACOTHERAPY (2001)
Willingness to pay for a quality-adjusted life year: In search of a standard
RA Hirth et al.
MEDICAL DECISION MAKING (2000)
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
